Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial

BACKGROUND: Doxorubicin chemotherapy is associated with cardiomyopathy. Dexrazoxane reduces cardiac damage during treatment with doxorubicin in children with acute lymphoblastic leukaemia (ALL). We aimed to establish the long-term effect of dexrazoxane on the subclinical state of cardiac health in s...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Prif Awduron: Lipshultz, Steven E, Scully, Rebecca E, Lipsitz, Stuart R, Sallan, Stephen E, Silverman, Lewis B, Miller, Tracie L, Barry, Elly V, Asselin, Barbara L, Athale, Uma, Clavell, Luis A, Larsen, Eric, Moghrabi, Albert, Samson, Yvan, Michon, Bruno, Schorin, Marshall A, Cohen, Harvey J, Neuberg, Donna S, Orav, E John, Colan, Steven D
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: 2010
Pynciau:
Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC3756093/
https://ncbi.nlm.nih.gov/pubmed/20850381
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(10)70204-7
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg